Assurion Labs, a US supplier of research-use-only peptides, has announced what it calls a Verified-Lot Standard, requiring every catalog peptide to meet at least 99% purity by reversed-phase HPLC before release. The announcement came via press release on November 19, 2026.
Under the standard, each lot gets an identity check, content quantification and contaminant screening, with results written onto a lot-matched Certificate of Analysis. Sample COAs are posted publicly, and the company says registered customers can pull the full COA for any lot using the number printed on the vial.
The purity number nobody explains
The most useful thing in the release is not the 99% figure, it is the explanation of why that figure alone is close to meaningless. HPLC purity measures how much of the UV-absorbing material in a sample is the target sequence, not how much of the powder in the vial is peptide at all.
Assurion Labs says a lot can be 99% pure by HPLC and still be only 60 to 85% peptide by weight, with the remainder made up of counterions such as TFA, bound water and salts. Labs calculating concentrations from fill weight, according to the company, can be off by 15 to 40% without knowing it.
What the COA covers
That is the stated reason for reporting net peptide content on every COA, alongside purity. Synthesis impurities that HPLC does detect, such as truncated or deletion sequences, are kept at or below 1% combined, the company says.
Each vial carries a lot number tied to its analytical data and release decision. Peptides are lyophilized, sealed and stored at minus 20 degrees Celsius before dispatch, then shipped on ice.
Who is verifying the verifier
The diagnosis of the market is blunt and, on the evidence of the last two years of regulator warnings, fair: purity numbers asserted but not shown, COAs reused across lots, vials whose contents do not match the label. The awkward part is that the fix here is also self-reported.
No independent auditor, accreditation body or third-party lab is named anywhere in the release. A supplier publishing its own COAs is a real improvement on publishing nothing, but it is still a supplier grading its own work.
Bottom line
Products are sold only to qualified researchers for in-vitro laboratory use, and the company states explicitly that its analytical findings are not claims of safety or efficacy. Whether verified-lot documentation becomes a market norm or stays a marketing differentiator is the question the release does not answer.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.